Geneoscopy Announces Formation of Scientific Advisory Board to Inform Strategy for the Advancement of Gastrointestinal Health – PR Newswire

Renowned Physicians and Academic Leaders to Provide Strategic Guidance for Geneoscopy's Upcoming Scientific and Regulatory Milestones

ST. LOUIS, June 21, 2022 /PRNewswire/ --Geneoscopy Inc.,a life sciences company focused on the development of diagnostic tests for gastrointestinal (GI) health, today announced the formation of its Scientific Advisory Board (SAB) comprised of leading experts in gastroenterology, oncology, and internal medicine. The SAB will provide strategic input based on their scientific knowledge and clinical expertise to help guide Geneoscopy through the development, regulatory and commercial phases for their RNA-based technology to improve GI health, starting with colorectal cancer.

The seven-member SAB includes:

"Gastrointestinal diseases affect 70 million Americans,1 and for some such as colorectal cancer, survival is highly dependent upon the stage of disease at diagnosis. The advancement of new technologies is critical for the early detection, diagnosis and potentially even prevention of these illnesses," noted Board member David Lieberman, M.D. "I am pleased to serve as the Chair of this esteemed group of thought leaders as we work together to shape the future of GI health and help guide Geneoscopy's efforts to maximize the potential of their promising technology to improve the standard of care for patients and providers."

"The establishment of our Scientific Advisory Board is a significant step forward in our mission to transform GI health. We are pleased to assemble such a distinguished panel of advisors and look forward to their deep insights as leading experts in their fields. Our SAB members' valuable guidance will inform the clinical and commercial advancement of our innovative RNA technology for other potential and future applications currently under investigation," stated Haytham Gareer, M.D., Ph.D., MBA, FACS, Chief Medical Officer.

About Geneoscopy Inc.

Geneoscopy Inc. is a life sciences company focused on the development of diagnostic tests for gastrointestinal health. Geneoscopy's lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded Breakthrough Device Designation from the U.S. FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Indicative of its breakthrough status, preliminary trials suggest that the diagnostic can detect these lesions at a higher rate than all existing noninvasive screening tests. Visitgeneoscopy.comto learn more.

Geneoscopy Inc. Forward-Looking Statements

The information contained in this release includes information about Geneoscopy's future plans concerning its noninvasive molecular test that can detect colorectal cancer and precancerous adenomas, and as such constitute forward-looking statements. These forward-looking statements are based upon the Company's reasonable estimates of future results or trends. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Geneoscopy's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Although the Company believes that its business plans and objectives reflected in or suggested by these forward-looking statements are reasonable, such plans or objectives may not be achieved, and the actual results may differ substantially from the projected results.

Media ContactSuzanne HaberGreen Room Communications[emailprotected]

SOURCE Geneoscopy Inc.

The rest is here:
Geneoscopy Announces Formation of Scientific Advisory Board to Inform Strategy for the Advancement of Gastrointestinal Health - PR Newswire